← Back to Search
Interleukin-2/liposomes Potentiate Immune Responses To A Soluble Protein Cancer Vaccine In Mice
Dean Johnston, S. R. Reynolds, J. Bystryn
Published 2005 · Biology, Medicine
Download PDFAnalyze on Scholarcy
A critical element in improving the potency of cancer vaccines, especially pure protein or peptide antigens, is to develop procedures that can strongly but safely increase their ability to induce immune responses. Here, we describe that encapsulation of a pure protein antigen and interleukin-2 (IL-2) together into liposomes significantly improves immune responses and tumor protection. Groups of C57Bl/6 mice were immunized weekly ×4 with –0.1 mg of ovalbumin (OVA) injected subcutaneously in PBS or encapsulated in liposomes with or without human recombinant IL-2. Control groups included mice immunized to irradiated E.G7-OVA cells (that express ovalbumin), or to PBS. Sera were collected and pooled by immunization group at baseline and at weeks 2 and 4 to measure antibody responses to OVA by ELISA. Splenocytes obtained at week 4 were tested for anti-OVA cellular responses by ELISPOT. Mice were then challenged to a lethal dose of E.G7-OVA cells to measure tumor-protective immunity. IL-2 liposomes caused no detectable toxicity. Antibody, CD8+ T cell, and tumor-protective immune responses were markedly enhanced in mice immunized to OVA + IL-2 in liposomes compared to mice immunized to OVA, either alone or encapsulated into liposomes without IL-2. These results indicate that IL-2 liposomes enhance antibody, cellular, and tumor-protective immune responses to immunization with a soluble protein. This may provide a simple, safe, and effective way to enhance the immunogenicity of vaccines that consist of pure protein antigens.
This paper references
Peptide-based vaccines for cancer immunotherapy
J. Brinkman (2004)
Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy
W. Kast (2004)
Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma
J. Bystryn (1992)
Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine
K. Miller (1995)
Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens
G. Phan (2003)
Potentiation of B16 melanoma vaccine immunogenicity by IL-2 liposomes
N Gershman (1994)
A Fully Synthetic Therapeutic Vaccine Candidate Targeting Carcinoma-Associated Tn Carbohydrate Antigen Induces Tumor-Specific Antibodies in Nonhuman Primates
R. Lo-Man (2004)
Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
Y. Akiyama (2004)
CD4-Directed Peptide Vaccination Augments an Antitumor Response, but Efficacy Is Limited by the Number of CD8+ T Cell Precursors1
H. Hanson (2004)
in liposomes : preliminary studies with IL - 2 , IL - 6 , GM - CSF and interferon - gamma
PM Anderson (1994)
HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
S. Reynolds (1998)
Therapeutic cancer vaccines: Using unique antigens
J. Lewis (2004)
Biopharmaceutics of liposomal interleukin 2, oncolipin.
M. Neville (2000)
Disease-driven T cell activation predicts immune responses to vaccination against melanoma.
D. Speiser (2003)
Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-gamma.
P. Anderson (1994)
Liposome encapsulated tumor-associated antigens elicited humoral and cellular immune responses in mice bearing tumor.
A. Alam (2001)
Sustained cytokine delivery for anticancer vaccination: liposomes as alternative for gene-transfected tumor cells.
F. Koppenhagen (1998)
Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2).
C. L. Nguyen (2003)
Liposomes Containing Interferon-Gamma as Adjuvant in Tumor Cell Vaccines
M. van Slooten (2004)
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.
P. Livingston (1994)
Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
S. Reynolds (2003)
Vaccine and antibody-directed T cell tumour immunotherapy.
S. Dermime (2004)
Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration.
P. Anderson (1992)
Vaccines for melanoma.
J. Bystryn (2002)
Progress on new vaccine strategies for the immunotherapy and prevention of cancer.
J. Berzofsky (2004)
Cancer immunotherapy: moving beyond current vaccines
S. Rosenberg (2004)
Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
J. Bystryn (2001)
Introduction of soluble protein into the class I pathway of antigen processing and presentation
M. Moore (1988)
Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
E. Hsueh (2003)
Multiepitope Trojan Antigen Peptide Vaccines for the Induction of Antitumor CTL and Th Immune Responses1
J. Lu (2004)
Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line.
Karl G. Kohlgraf (2003)
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
M. Lotem (2004)
Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients1
D. Atanackovic (2004)
Double-Blind Trial of a Polyvalent , Shed-Antigen , Melanoma Vaccine 1
J. Bystryn (2001)
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
Y. Sato (2004)
Immune responses to human tumors: development of tumor vaccines.
C. Platsoucas (2003)
Cancer Immunotherapy: A Treatment for the Masses
J. Blattman (2004)
Response Rates of Patients With Metastatic Melanoma to High-Dose Intravenous Interleukin-2 After Prior Exposure to Alpha-Interferon or Low-Dose Interleukin-2
D. M. Weinreich (2002)
The fate of interleukin-2 after in vivo administration.
J. Donohue (1983)
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
C. Slingluff (2003)
Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.
S. Reynolds (2000)
Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
E. Davila (2003)
Immunotherapy of melanoma: the good news, the bad ones and what to do next.
F. Marincola (2003)
Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation.
O. C. Krup (1999)
This paper is referenced by
Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy.
Suzanne R. Foster (2010)
PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity
Jie Gao (2008)
Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine.
Dean Johnston (2006)
Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
S. Song (2007)
TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines
Dean Johnston (2006)
Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy.
M. Shaker (2009)
Synthetic nanovaccines for immunotherapy
Min Luo (2017)
Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine.
X. Huang (2011)
Cancer vaccines: preclinical studies and novel strategies.
C. Palena (2006)
Liposomal delivery of proteins and peptides
Janani Swaminathan (2012)
Therapeutic efficacy of Bifidobacterium longum-mediated human interleukin-2 with endostatin or TRAIL in transplanted tumors in mice.
Y. Yin (2012)
Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease
O. Boyman (2006)
Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells
Y. Yang (2006)
Rational combination immunotherapeutic approaches for effective cancer treatment.
Cao Dai Phung (2019)
Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics.
A. Grimaldi (2017)
4.419 – Vaccine and Immunotherapy Delivery
D. J. Irvine (2011)
Particle-mediated delivery of cytokines for immunotherapy.
D. Christian (2012)